Nuvation Bio (Nuvation Bio) EV-to-EBIT : 0.00 (As of May. 01, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nuvation Bio's Enterprise Value is $0.00 Mil. Nuvation Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-99.82 Mil. Therefore, Nuvation Bio's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Nuvation Bio's EV-to-EBIT or its related term are showing as below:

During the past 4 years, the highest EV-to-EBIT of Nuvation Bio was 3.92. The lowest was -5.47. And the median was 0.00.

NUVB.WS's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.725
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nuvation Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil. Nuvation Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-99.82 Mil. Nuvation Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

Nuvation Bio EV-to-EBIT Historical Data

The historical data trend for Nuvation Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio EV-to-EBIT Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

1.98

2.77

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial											1.98	2.37	2.19	3.11	2.77

Competitive Comparison of Nuvation Bio's EV-to-EBIT

For the Biotechnology subindustry, Nuvation Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's EV-to-EBIT falls into.

Nuvation Bio EV-to-EBIT Calculation

Nuvation Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-99.822
	=	0.00

Nuvation Bio's current Enterprise Value is $0.00 Mil.
Nuvation Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.82 Mil.

Nuvation Bio (NYSE:NUVB.WS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nuvation Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-99.822	/	0
	=	%

Nuvation Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil.
Nuvation Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.82 Mil.

Nuvation Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).